Brand profile · Biotechnology Research

Radiopharm Theranostics

Radiopharm Theranostics is a Biotechnology Research brand in Sydney. Ownership is privately held; it publishes at radiopharmtheranostics.com. It holds one address on record, all in Australia. The record counts 24 people. Tagged cancer, diagnostics and health. One Australian registration (ABN) is a confirmed match. Its latest round on record is Post IPO equity, US$5.0M. It is listed alongside two similar brands, mostly in Pharmaceutical Manufacturing.

Profile live Privately Held Founded 2021 1 entity ABN 1 office country US$ 5.0M Post IPO equity
Registry verified · ABR

Key facts

Counted staff
24
self-reported 2–10 band
Founded
2021
5 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
3
Post IPO equity · Feb 2025 · US$ 5.0M
Company type
Privately Held
self-reported
Use this profile Compare Your shortlist

Legal entity

1 brand → 1 confirmed entity
  • RADIOPHARM THERANOSTICS LIMITED

    ABN57647877889

    VICHigh confidenceMatched on exact nameABR

Legal entities

Radiopharm Theranostics: 1 registry entityRadiopharm Theranostics is linked to 1 registry entity: RADIOPHARM THERANOSTICS LIMITED (ABN 57647877889, candidate).Radiopharm TheranosticsRADIOPHARMTHERANOSTICS LIMITEDABN 57647877889Candidate · High confidence
Show as table · Radiopharm Theranostics: 1 registry entity
Radiopharm Theranostics: 1 registry entity
RADIOPHARM THERANOSTICS LIMITEDABN 57647877889
Confirmed matches0 of 1

A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.

Description

Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.

Specialties

All 27 specialties
  • nuclearmedicine
  • therapeutic
  • diagnostics
  • biotechnology
  • biotech
  • cancerresearch
  • cancer
  • clinicaltrials
  • medtech
  • health
  • radioactivedrugs
  • drugdiscovery
  • breastcancer
  • lungcancer
  • neckcancer
  • pancreaticcancer
  • braincancer
  • glioblastoma
  • peptides
  • smallmolecules
  • monoclonalantibodies
  • antibodies
  • breastcancerimaging
  • patients
  • HER2
  • radiopharmaceuticals
  • therapeutics

Locations

Country footprint

Offices in 1 countryCountry footprint: 1 country, primary AU. Codes: AU.1 countryprimary AUAU
Show as table · Offices in 1 country
Offices in 1 country
Countries1
Primary countryAU

All codes: AU

Addresses

  • AUSydneyPrimary

Grid intelligence Members

Funding

Last round · 9 February 2025US$ 5.0MPost IPO equity · investor: Lantheus Holdings
Rounds3
Round typePost IPO equity · secondary transaction
Amount (USD)5,000,000
Stage rank6
Investors named1
Since last round11 mo

Funding

3 funding roundsFunding timeline. Latest round 9 Feb 2025: Post IPO equity, US$ 5.0M.20212026Post IPO equityUS$ 5.0M3 rounds
Show as table · 3 funding rounds
3 funding rounds
Rounds3
Axis2021 to 2026
Post IPO equity · 9 Feb 2025US$ 5.0M

Dated rounds only. The axis ends at the date this profile was last observed, not at today.

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss

People & contacts

4 employee profiles on record · names withheld.

Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.

Counts only. No names are stored here, and none are served.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

Which legal entity operates under Radiopharm Theranostics?

One Victoria entity on the ABR. RADIOPHARM THERANOSTICS LIMITED (ABN 57 647 877 889), high confidence.

How many people work at Radiopharm Theranostics?

The record holds 24 counted staff profiles at January 2026, above the self-reported 2–10 band.

Where does Radiopharm Theranostics have offices?

One address on record, Australia only. Primary: Sydney.

Has Radiopharm Theranostics raised funding?

Three rounds. Latest 9 February 2025: post IPO equity, US$5,000,000, investor Lantheus Holdings.

What does Radiopharm Theranostics list as its specialties?

27 tags on the brand's own list, among them cancer, diagnostics and health.

Which companies are listed alongside Radiopharm Theranostics?

6 profiles list Radiopharm Theranostics as a peer — 68th percentile in Biotechnology Research. It lists ten peers of its own. Clarity Pharmaceuticals lists it back.

What is Radiopharm Theranostics's website?